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ABSTRACT
Introduction: HIV-associated neurocognitive disorders 
(HAND) are the subject of many studies, some of them 
reporting a prevalence of up to 50 percent. Objectives: To 
determine the prevalence and factors associated with HIV 
neurocognitive disorders (HAND) in a cohort of HIV-1-
infected patients in São Paulo city, Brazil. Methodology: 
Descriptive cross-sectional study including 106 HIV-1-infected 
patients, employing direct interview and neuropsychological 
tests, applied by trained neuro-psychologists with expertise in 
the tests. Other, similar assessment tools we used were Brief 
Neurocognitive Questionnaire, International HIV Dementia 
Scale, Lawton Instrumental Activities of Daily Living, 
Hospital Anxiety and Depression Scale, Social Support 
Scale for People with HIV/Aids, Assessment of Adherence 
to Antiretroviral Therapy Questionnaire, and a complex 
neuropsychological assessment. Results: We included 106 
patients from May 2015 to April 2018. We found a high 
prevalence of HAND in our patients (45%), with 27.5% 
presenting asymptomatic neurological impairment (ANI) and 
17.5% mild neurological dysfunction (MND); only one patient 
presented HIV-associated dementia (HAD) (0.9%). Women 
were more likely to have MND (52.9%) and the only case of 
HAD was also female. The high prevalence of neurocognitive 
disorders was independent of the immunological status, use 
of efavirenz, or virological control. Conclusions: This study 
may mirror the national and international scenarios, showing 
a high prevalence of HAND (45%) and the prevalence of 
some risk factors, in special among women.
Key word: HIV; HIV-neurocognitive associated disorder 
(HAND); HIV-associated dementia (HAD), Brazil.
RESUMO
Introdução: As doenças neurocognitivas associadas ao 
HIV (HAND), são o assunto de muitos estudos, alguns 
deles relatando uma prevalência de até 50 por cento. 
Objetivos: Determinar a prevalência e os fatores associados 
aos distúrbios neurocognitivos do HIV (HAND) em uma 
coorte de pacientes infectados pelo HIV-1 na cidade de São 
Paulo, Brasil. Metodologia: Estudo transversal descritivo 
incluindo 106 pacientes infectados pelo HIV-1, utilizando 
entrevista direta e testes neuropsicológicos, aplicados por 
neuropsicólogos treinados com experiência nos testes. 
Foram utilizados também: Questionário Neurocognitivo 
Breve, Escala Internacional de Demência do HIV, Atividades 
Instrumentais de Vida Diária de Lawton, Escala Hospitalar de 
Ansiedade e Depressão, Escala de Apoio Social para Pessoas 
com HIV / Aids, Avaliação da Adesão à Terapia Antiretroviral 
Questionário e uma bateria de avaliação neuropsicológica 
complexa. Resultados: Foram avalaidos 106 pacientes de maio 
de 2015 a abril de 2018. Foi observado uma alta prevalência de 
HAND em nossos pacientes (45%), com 27,5% apresentando 
comprometimento neurológico assintomático (ANI) e 
17,5% comprometimento cognitive leve (MND); apenas 
um paciente apresentou demência associada ao HIV (DAH) 
(0,9%). As mulheres eram mais propensas a ter MND (52,9%) 
e o único caso de HAD também era do sexo feminino. A alta 
prevalência de distúrbios neurocognitivos foi independente do 
estado imunológico, uso de efavirenz ou controle virológico. 
Conclusões: Este estudo pode espelhar o cenário nacional 
e internacional, mostrando uma alta prevalência de HAND 
(45%) e a prevalência de alguns fatores de risco, em especial 
entre as mulheres.
Palavras-chave: HIV; Transtorno neurocognitivo associado 
ao HIV (HAND); Demência associada ao HIV (HAD), Brasil.
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INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) 
infection remains a global public health problem (1). The 
introduction of combined antiretroviral therapy (cART) 
turned AIDS a chronic disease amenable to control, 
reducing morbidity and death.  Although good adherence 
to cART provides effective plasma viral suppression, the 
rates of HIV-associated neurocognitive disorders (HAND) 
are increasing, especially in their milder forms (2-6), and 
in developing countries, such as Brazil (9).
The profile of neurocognitive manifestations among 
people living with HIV (PLWH) changed dramatically 
in the ART era, characterized by a reduced incidence of 
HIV Associated Dementia (HAD) but increased Mild 
Neurocognitive Disorder (MND) and Asymptomatic 
Neurocognitive Impairment (ANI) (1). Currently, 
prevalence is estimated between 15-30% for ANI, 20-50% 
for MND and 2-8% for HAD (1,2,8). These proportions are 
constant regardless of the location of the studies, as many as 
half of those infected with HIV in Europe and the US may 
have some degree of cognitive impairment, predominantly 
asymptomatic (5). In Brazil, it has been already shown that 
the prevalence of HAND ranges from 4.6% to 52.4% (7), 
while In Latin America the prevalence of HAND varies 
from 26.8% to 45%.(8-10). However, most data come 
from countries with distinct characteristics, particularly 
those regarding the level of education and income (8-17). 
Here we aimed to identify the prevalence of HAND in a 
cohort of HIV-1-infected subjects with high adherence to 
cART, HIV replication under control and low prevalence 
of opportunistic diseases, as reported previously (15). 
METHODS
This study was carried out with outpatients from 
Hospital das Clínicas da Faculdade de Medicina da 
Universidade de São Paulo (HC), between May 2015 
and April 2018. One-hundred and six patients were 
selected according to inclusion and exclusion criteria. The 
inclusion criteria included presence of HIV antibodies 
in serum (ELISA and Western Blot), age older than 18 
years, at least four years of formal education, being in 
use of cART and in regular medical follow-up over the 
last year and ability to understand and sign an informed 
consent form. The exclusion criteria were: prior or 
current diagnosis of documented neurological conditions 
(traumatic, metabolic, vascular or degenerative) that might 
interfere with the cognitive performance assessment, co-
infection (e.g. HCV, HBV and HTLV), use of psychoactive 
substance, and inability to understand essential content for 
neuropsychological evaluation. The study was approved 
by The Ethical Board of the  Hospital  (Cappesq  number 
982.307) and an informed signed consent was obtained 
from all participants prior to study inclusion, who signed 
and took home one form also signed by the investigator. 
The assessment tools we used were: sociodemographic 
questionnaire, Brief Neurocognitive Questionnaire, 
International HIV Dementia Scale (IHDS) (18), Lawton 
Instrumental Activities of Daily Living (19), Hospital 
Anxiety and Depression Scale (HADS) (20), ASSIST - 
Screening with alcohol, tobacco and other substances (21), 
Social Support Inventory for People Who Are Positive or 
Have Aids (22), CEAT-VIH - Assessment of Adherence to 
Antiretroviral Therapy Questionnaire (23), and a complete 
neuropsychological battery (24-26). All volunteers were 
submitted to the same batteries of neurological tests, 
performed by the same team (MRG and CFG) at the same 
clinical site, in an office exclusive for this activity. The 
investigators were blinded for the HIV serostatus and the 
same battery was used throughout  the entire study. One 
extra visit was scheduled to disclose tests results. Two 
patients with dementia had their relatives participating in 
the appointment for help with the evaluation. 
 We determined patients neuropsychological profile by 
complex neuropsychological assessment, consisting of the 
following instruments: Memory: Operating and Working – 
Digits (24), Episodic Auditory - The Rey Auditory-verbal 
learning test (RAVLT) (25); Speed Information Processing: 
Codes (24); Executive Function: Phonemic Verbal Fluency 
Test (FAS) and Categorical Verbal Fluency (Animal 
Naming) (26), - Trail Making Test A and B (26); and Motor 
Skills: Grooved Pegboard (26). After neuropsychological 
assessment, patients were classified according to HAND 
categories adapted from the American Academy of 
Neurology, also known as Frascati’s Criteria (3). 
 We extracted clinical, laboratory and demographical 
data from the electronic medical records (PRONTMED) 
and/or from direct interview, previously to the 
neuropsychological test application. HIV viral load and 
T-CD4 cells count were performed at the laboratory of 
the Hospital (27). We checked cART regimens using the 
Hospital pharmacy database (SIGH, Prodesp). We gave 
special attention to efavirenz use due to the possibility 
of neurological side effects, which might affect patient’s 
performance on neuropsychological tests. 
1.1. Statistical Analysis
We created a database with our data and displayed our 
results in frequency tables. For the neuropsychological 
performance comparison among groups we performed 
analysis of variance for independent samples with one 
factor (one-way ANOVA), to identify potential covariates 
associated with the participants’ neuropsychological 
performance (gender, age, education and depression). After 
the establishment of the variables, an analysis of three 
groups was performed (ANCOVA) to eliminate the effect 
of those co-variates. We used Mann-Whitney test after 
Kolmogorov-Smirnov normality test, and Bonferroni´s 
Post-Hoc test, to identify statistical differences in pairs of 
groups. We performed all quantitative analyses with the 
aid of the statistical package SPSS (21.0); we set p <0.05 
as the significance level.
RESULTS
 We studied 24.6% of our active patients (106 of the 
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430 subjects who comprise the whole cohort). Table 1 
shows the demographic characteristics of the three groups 
of neurocognitive impairment. HIV-1-infected subjects 
were predominantly male (n = 79, 74.5%), single (n = 51, 
48.1%), their mean age was 46.36 years (SD ± 11.93), 
their mean schooling was 12.32 years (± 3.67) and 89.5 
percent were employed at the time of the evaluation; there 
were no difference for those variables. Criteria for HAND 
Table 1. Characterization of the 106 HIV-infected participants in relation to age, gender, education level, marital status 
and occupation.







Gender Male 49 (85.9%) 22 (68.75%) 8 (47.0%) 0.004
Female 8 (14.0%) 10 (31.2%) 9 (52.9%)
Age* 45.70(±11.7) 43.72 (±12.7) 46 ±12 0.47
Educational
level*
13.20 (±4.0) 12.7 (±4.0) 11 ± 4 0.37
Marital status Single 34 (59.6%) 13 (40.6%) 4 (23.5%) 0.26
Married 17 (29,8%) 15 (46,9%) 10 (58,8%)
Divorced 4 (7.0%) 1 (3.1%) 2 (11.7%)
Widower 2 (3.5%) 3 (9.3%) 1 (5.8%)
Occupation Home 1 (1.7%) 1 (3.1%) 1 (5.8%) 0.29
Employee 51 (89,5%) 25 (78,1%) 10 (58.8%)
Unemployee 2 (8.7%) 4 (22.2%) 5 (29.4%)
Retiree 3 (13%) 2 (11.1%) 1 (5,9%)
Notes: P value <0.05 (T-Mann-Whitney after Kolmogorov-Smirnov normality test); SD = standard deviation. One case with HIV-associated 
dementia (HAD) was not present here.
ANI: Asymptomatic; MND: Mild neurocognitive Disease
classification indicated that 49 men (46.2%) and 8 (7.5%) 
women had a normal cognitive performance ; 32 patients 
(30.2%) had ANI, 22 (20.7%) of whom   were men and 
10 (9.4%) were women; 17 (16%) had MND, 8 (7.5%) of 
whom were men and 9 (8.4%) were women. One patient 
(a woman) had a diagnosis of HAD (0.9%), but failed 
to complete most of the neuropsychological tests of the 
evaluation battery, and was excluded from further analysis.
In summary, from 27 women (100%) who completed 
the entire evaluation, 8 (29.6%) had a normal performance, 
10 (37%), had ANI, and 9 (33.3%) had MND.  Including 
the patient who had HIV-associated dementia (HAD), 
a total of 20 women had HAND, or 71.4%. In contrast, 
among 79 men, 49 (62%) presented normal performance, 
22 (27.8%) had ANI, and 8 (10.1%) had MND,  the total of 
men who had HAND reaching 30 (38%). A comparison of 
the genders’ proportions,was  significant (p=0.001).
Graph1: Distribution of HAND frequency according to 
sex.
In the distribution of cognitive changes among people 
living with HIV (PLWH),   the higher frequency of women 
with the MND form (33.3%), when compared to men 
(10.1%), deserves attention. Pearson’s correlation showed 
that years of schooling (rho = -0.511 and p = 0.002) was 
associated with the outcome, that is,, the lower the schooling 
the more severe the HAND. Other variables did not reach 
statistical significance, such as age (p = 0.268), systemic 
diseases (p = 0.952) like diabetes (n = 10), hypertension 
(n=14) and dyslipidemia (n= 19); duration of the infection 
(p = 0.09, mean: 18.40 ± 7.95 years), CD4+ T cell count 
(p = 0.52, 751 ± 366 cells/mm3) and plasma HIV RNA 
viral load (p = 0.815) also were not associated with the 
outcome. Only eight patients (7.5%) had a detectable viral 
load (median <200 copies/mL), but no association with 
HAND was found (Table 2). We did not find association 
of anxiety and depression with HIV status. Although there 
was no significant difference, we did observe that MND 
forms had a lower score on the compliance scale (CEAT), 
the main reason being forgetfulness in relation to taking 
medications and also showing less emotional support 
(Table 3). As a rule patients showed a poor performance in 
the following tests: digits, episodic memory of immediate 
recall, post-interference and late, Trail A and B, FAS and 
Animals, Grooved dominant hand, namely short-term 
memory, episodic memory of immediate recall, post 
interference, sustained and alternating attention, phonetic 
and categorical verbal fluency, and dominant hand speed, 
whereas in the following tests: codes and non-dominant 
hand grooved, that is, in cognitive functions of speed of 
processing and motor speed results were better (Table 4). 
Women performed worse than men in digits (p = 0.01), 
trail making A (p = 0.03) and grooved pegboard non-
dominant hand (p = 0.03). In addition, women showed 
Gascon MR et al. Prevalência HAND em São Paulo.
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more impairment than men in working memory, sustained 
attention and non-dominant hand motor speed. There was 
no statistical difference regarding anxiety (p = 0.52) and 










693 ± 293 741 ± 310 707 (±340) 0.82
HIV RNA plasma
viral load
   Undetectable 51 (89.4%) 30 (93.7%) 14 (82.3%) 0.46
Detectable 6 (10.5%) 2 (6.2%) 3 (17.6%)
Efavirenz
Use  23 (40.3%) 8 (44.4%) 6 (42.8%)
No use  34 (59.6%) 10 (55.5%) 8 (57.1%) 0.36
*= n (%). p<0.05. Undetectable plasma viral load <40 copies/ml; American Academy of Neurology 2007 - Frascati Criteria for HAND.










6.18 ± 4.64) 5.45 ± 9.47 9.47 ± 4.30 0.04*
Depression and Hospital
Anxiety Scale D
5.16 ± 4.39 4.97 ± 4.60 8.12 ± 3.80 0.03*
Questionnaire assessing 
adherence to antiretroviral 
treatment (CEAT)
82.00 ± 8.31 79.78 ± 7.36 77.2 ± 8.02 0.08
Instrumental Social Support 42.51 ± 13.7 44.1  ± 9.52 41.41  ± 11.43 0.73
Emotional Social support 44.96 ± 11.48) 46.12 ± 9.23 38.82  ± 13.52 0.08
Notes: CEAT: Questionnaire assessing adherence to antiretroviral treatment; ISS: Instrumental and Emotional Social Support, Social Support 
Scale for People Living with HIV/AIDS. HAND: American Academy of Neurology 2007 - Frascati Criteria. Each scale was 1:100.







P value Post Hoc
Memory
Digit Span 60.33 ± 24.45) 52.59 ±  26.18 41.11 ± 26.15 0.029* B
RAVLT – IM 35.93 ± 24.76) 17.83 ± 18.61 12.48 ± 15.9) <0.001* A e B
RAVLT – PI 38.20 ± 24.63) 21.32 ± 22.31) 19,70 ± 18.93 0.001* A e B
RAVLT – TR  37.18 ± 24.8 16.33 ± 20.42)  14.81 ± 16.41 <0.001* A e B
RAVLT – RC 11.45 ± 3.9 10.9 ± 3.04 8.31 ± 5.7 0.001* A e B
Attention 
Trail Making A 51.98 ± 29.66) 35.30 ± 29.66 24.78 ± 23.66 0.001* A e B
Trail Making B  52.77 ± 25.81 24.68 ± 29.06 20.55 ± 30.78 <0.01* A e B
Processing Speed
Digit Symbol Coding 69.78 ± 20.50)  53.71 ± 27.65 53.31 ± 30.59 0.005* A
Executive Function
F.A.S. 39.18 ± 26.84  23.06 ± 22.91 15.70 ± 17.7 0.001* A e B
Animals 55.85 ± 30.06 51.09 ± 25.61 42.62 ± 29.8 0.24
Cognitive Screening
Int. HAD 10,61 ± 1.17 10.33 ± 1,49 9.74 ±1.76 0.07
Motor Speed
Gr – MD 41.02  ±  30.01 34.55 ± 29.53 20.35 ± 28.75) 0.045* B
Gr- MND 39.11 ± 2 7.87 26.66 ± 23.74 14.40 ± 20.40 0.002* B
(DP). p<0,05. RAVLT: The Rey Auditory-Verbal Learning Test; (IM: immediate, PI: post-interference, TR: late, RC: recognition); IHDS: 
International HIV Dementia Scale; Gr, Grooved Pegboard, MD: dominant hand; MND: non-dominant hand.  F.A.S: Fuency VerbalA: No 
change x ANI; B: No change x MND; C: ANI x MDN.
depression (p = 0.82), which may influence performance. 
Age (p = 0.90) and education (p = 0.08) variables were also 
not statistically different.
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DISCUSSION
We found a high prevalence of HAND (46.2%) in its 
two less severe forms, ANI (30.2%) and MND (16%), and 
only one case of dementia in our sample. These results 
confirm that a considerable number of patients continue to 
exhibit measurable cognitive dysfunction in the cART era 
in Brazil, where the potential availability of treatment is 
universal and free of charge (7). The overall frequency of 
HAND in our population was similar to that found in other 
studies, around 46% (ranging from 34 to 58%). However, 
another study using the same NP tests for 412 patients 
from other referral center found a 73.5% prevalence of 
HAND, being 50.9% ANI, 16.2% MND and 6.3% HAD 
(7). One possible reason for this difference may be related 
to the kind of population followed at each service. The 
better performance of our patients may be associated with 
their lower overall prevalence of morbidity: for instance, 
many were referred asymptomatic from blood banks to 
our service, and many of them never had any opportunistic 
infection. Similarly, a study found 84% prevalence of 
HAND among patients with previous self-perception of 
cognitive complaints (24% ANI, 52% MND, 8% HAD) 
and 64% among those who did not complain of difficulties 
in daily life (60% ANI) (43). The results of this study 
were similar to those obtained in other countries in Latin 
America (8-11).
There are few data on the prevalence of HAND in 
Brazil, their numbers ranging from 4.6% to 52.4% (5, 
28-31). Such discrepancies, including the findings of 
this study, can be explained by different criteria used to 
define HAND, diversity of instruments used or size of the 
population studied. Also, the default of control variables 
may influence the results of neuropsychological tests, 
such as level of schooling, unemployment and depression. 
Regional features can also be important, as well as the type 
of co-morbidity and the prevalent HIV subtype. We tried 
to minimize these interferences during this study, using 
several forms to improve the quality of our database.
In this study, a higher prevalence of MND cases was 
observed in women. HIV-positive women may be at higher 
risk of cognitive decline than HIV-positive men, due to 
their high prevalence of psychosocial and mental health 
disturbances (32,33). Psychological suffering alone does 
not fully explain neurocognitive impairment among HIV-
positive individuals. However, given the higher prevalence 
of depression among women compared to men, we speculate 
that the effects of depression on neuropsychological 
function are more widespread among HIV-positive women 
(34). We did not find a gender difference in mean viral 
loads values that could be associated with neurocognitive 
changes.   
A study carried out in the United States found significant 
differences in cognitive function between men and women 
with HIV. Cognitive impairments are more prevalent in 
black women (52%), affecting mainly the area of memory. 
Low cognitive reserve, low reading level and unfavorable 
socioeconomic conditions were considered risk factors 
for cognitive impairment (35). Neuropsychological 
performance in a community sample of 237 PLWH 
compared to HIV-uninfected women was a significant 
predictor of slower psychomotor speed (36).
Neurocognitive performance testing in 149 HIV-positive 
women and 82 HIV-negative women enrolled in the 
Women’s Interagency HIV Study (WIHS) demonstrated  a 
psychomotor decline in PLWH when compared to healthy 
controls. In the intra-group analysis of women with HIV 
those not in use of antiretroviral therapy, compared to 
those undergoing treatment, had twice the risk of cognitive 
impairment, further supporting viremia as essential for 
HAND (37).
In this study, we found association of mood/affective 
symptoms with the outcome. Patients with late start 
of cART or recurrent depression may have significant 
cognitive and functional disturbances. On the other 
hand, these changes and symptoms may be due to a 
process of evolution of neurological-based cognitive 
impairment (38). However, a closer neuropsychological 
evaluation can trace the cognitive profile of those patients, 
helping with the differential diagnosis. In this study, all 
protocols were evaluated individually by an experienced 
neuropsychologist, avoiding false ANI and MND 
diagnosis.
Furthermore, it is important to emphasize that, other 
than HIV infection, no other cause seems likely to explain 
the presence of HAND, as patients with major depression, 
active drug dependence or opportunistic infection were 
excluded. Patients with the MND form also reported lower 
level of social and emotional support from their contact 
network, due to their seropositive condition. It seems 
advisable that, in addition to performing regular physical 
activity, a continuous stimulation of brain activities through 
social interactions and intellectual activities is encouraged 
to avoid cognitive dysfunction (6).
The cognitive profile of our patients without 
neurocognitive impairment was similar to those with 
ANI. There are controversies in the literature on both the 
definition, the significance and prognosis of patients with 
ANI. While some authors have shown that individuals 
with ANI may develop more severe forms of impairment, 
others have stressed that the definition of ANI is not strict 
and that the false positive rate is high (39, 40). However, 
regardless of the different opinions, HAND without 
functional consequences in daily life (asymptomatic 
neurocognitive impairment) is still the most frequent form 
(2, 9). The current classification of HAND by Frascati’s 
criteria, particularly of the ANI form, may overestimate the 
prevalence of this condition, since the definition of ANI is 
not strict and its application results in approximately 20% 
of the population being classified as abnormal, that is, 
false-positives, what is an unacceptable rate (40).
Our study has some limitations, such as its sample size 
(24.6% of the cohort). We intend to perform neuroimaging 
in the future, what may further enhance the precision of our 
findings. Despite those limitations, we sought to control for 
confounding factors, such as age, gender and education, as 
well as for confounders for the diagnosis of HAND, such 
Gascon MR et al. Prevalência HAND em São Paulo.
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as major depression and co-infection. Another limitation of 
the study is lack of control group, but Brazilian normative 
tables were used in the correction of the instruments used 
in this study (24-26).
On this study, we employed a complex neuropsychological 
assessment compared to other studies. In addition to the 
cognitive screening test (IHDS), we used neuropsychological 
instruments that enable a better understanding of the higher 
cognitive functions, allowing a greater precision in the 
detection of cognitive impairment. Usually, the studies 
have used a screening battery made up of three or four 
neuropsychological instruments (28-31).By contrast, in the 
present study, seven neuropsychological instruments were 
used, in addition to the IHDS, increasing the rigor of the 
rating. Our patients have a high degree of adherence to 
cART, with over 95% adherence and viral load detection 
(17). Such characteristics make this cohort somewhat 
specific compared to other Brazilian cohorts. Finally, we 
found a high prevalence of HAND (46.2%), mainly among 
women. A longitudinal follow-up to of such patients is very 
important, in order to  address the incidence and additional 
risk factors associated with HAND in Brazil, particularly 
concerning the gender differences we found.  
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